
    
      This is a prospective, randomized, single-blind, active drug controlled multicenter clinical
      research and the study would enrolled a total of 380 AMI patients undergoing percutaneous
      coronary intervention (PCI) to one of two antithrombotic regimens: bivalirudin alone, or
      unfractionated heparin alone. All enrolled patients would be followed-up to 30 days. The
      purpose of the study is to evaluate the efficacy and safety of bivalirudin in AMI patients
      with DES.
    
  